AMR500 experts at the 7th AMR Conference in B...How to stop hard-to-diagnose, treatment-resistant microbial pathogens was discussed by experts from 13 countries at the 7th AMR Conference in Basel. more ➔
financingVitestro raises €12m in Series A financi...With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market. more ➔
financing European VCs join US$105m financing of US... Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis … more ➔
Neurodegenerative disorders are being foug...Danish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases. more ➔
M&APfizer-Seagen: Acquisition in the worksPfizer strengthens its oncology portfolio by acquiring Seagen, the biotech specialist in antibody-drug conjugates technology. more ➔
financingIktos SA raises €15.5m in Series A finan... Paris-based AI-inspired drug discovery specialist Iktos SA has closed a €15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics. more ➔
partnershipCollaboration to fight cancerThe charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer. more ➔
financingNoema Pharma AG closes Series B financingNoema Pharma AG receives €104m in oversubscribed Series B financing round to advance its central nervous system pipeline. more ➔
IPOOculis lists at Nasdaq through SPAC mergerThe eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp. more ➔
financingMoney for AI-powered drug discoveryAntiverse Ltd.’s AI identified eight antibodies with therapeutic potential for humans and raised €2.8m in funding for continued in-house development. more ➔
